22-September-2023 Version: 1.2



Gemcitabine Injection

SAFETY DATA SHEET

North America GHS

According to Federal Register / Vol. 77, No. 58 / Monday, March 26, 2012 / Rules and Regulations & the Hazardous Products Regulation (February 11, 2015) & NORMA Oficial Mexicana NOM-018-STPS-2015

1. IDENTIFICATION

Product identifier

Product Name: Gemcitabine Injection

Synonyms: Gemcitabine Injection, USP; Gemcitabine Injection 200 mg/5.26 mL; Gemcitabine Injection 1 g/26.3 mL; Gemcitabine Injection 2

g/52.6 mL

Other means of identification

Other Information: No other information

Recommended use of the chemical and restrictions on use

Recommended Use: Pharmaceutical. Use only as directed. Refer to product insert for usage instructions and product information.

Uses advised against: No information available. Details of the supplier of the safety data sheet

Mylan Inc.

Robert J. Coury Global Center

1000 Mylan Blvd.

Canonsburg, PA 15317, USA

+1.724.514.1800

SDScontact@viatris.com **Contact e-mail:**

For any suspected reports of adverse events, product quality complaints or medical/product information questions, please email:

druginfo@viatris.com

Emergency telephone number

Emergency Telephone: 24 hr. Emergency Contact ChemTel

International: +1-813-248-0585 US & Canada: 1-800-255-3924

Mexico: 800-099-0731

2. HAZARDS IDENTIFICATION

Pharmaceutical Agent – Handling of this product in its final form presents minimal occupational exposure risk

Patients/Consumers: Please refer to the product information insert or product label for appropriate consumer-specific information about this product when used according to the physician's directions

Classification

Germ cell mutagenicity, Category 2

Carcinogenicity, Category 2

Reproductive toxicity, Category 1A

Specific target organ toxicity (repeated exposure), Category 1 (Bone marrow)

Label elements



22-September-2023

Signal word: Danger

H341 - Suspected of causing genetic defects **Hazard statements:**

H351 - Suspected of causing cancer

H360 - May damage fertility or the unborn child

H372 - Causes damage to organs through prolonged or repeated exposure

1/6

Gemcitabine Injection NA SDS

Precautionary Statements - Prevention: Obtain special instructions before use

Do not handle until all safety precautions have been read and understood Wear protective gloves/protective clothing/eye protection/face protection

Do not breathe dust/fume/gas/mist/vapors/spray

Wash face, hands and any exposed skin thoroughly after handling

Do not eat, drink or smoke when using this product

IF exposed or concerned: Get medical advice/attention **Precautionary Statements - Response:**

Precautionary Statements - Storage: Store locked up

Precautionary Statements - Disposal: Dispose of contents/container to an approved waste disposal plant

Other Hazards

Cytotoxic agent. May cause skin irritation. May cause eye irritation.

Unknown acute toxicity No information available

3. COMPOSITION/INFORMATION ON INGREDIENTS			
Chemical name	CAS No	Weight-%	Hazard statements
Gemcitabine Hydrochloride	122111-03-9	1 - 5%	H302 - Harmful if swallowed
			H315 - Causes skin irritation
			H319 - Causes serious eye irritation
			H341 - Suspected of causing genetic defects
			H351 - Suspected of causing cancer
			H360 - May damage fertility or the unborn child
			H372 - Causes damage to organs through prolonged or repeated
			exposure

4. FIRST AID MEASURES

This is a pharmaceutical product in its final form. The risk of harmful exposure in the workplace is limited; however, the following guidance may be used as needed.

Description of first aid measures

Overdose: Refer to information on package labeling and packaging. In case of overdose, get medical help or contact a Poison Control Center right away.

General advice: Show this safety data sheet to the doctor in attendance. IF exposed or concerned: Get medical advice/attention.

Inhalation: IF INHALED: Remove to fresh air and keep at rest in a position comfortable for breathing. Get medical attention immediately if symptoms occur.

Skin contact: Wash off immediately with soap and plenty of water. If skin irritation or rash occurs: Get medical advice/attention.

Eye contact: In case of eye contact, immediately flush eyes with plenty of water for at least 15 minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists: Get medical advice/attention.

Ingestion: Do not induce vomiting without medical advice. Rinse mouth thoroughly with water. Get medical attention if symptoms occur.

Self-protection of the first aider: First aider: Pay attention to self-protection. Do not breathe dust/fume/gas/mist/vapors/spray. Avoid contact with skin, eyes or clothing. Use personal protective equipment as required.

Most important symptoms and effects, both acute and delayed

Symptoms: May cause skin irritation. May cause redness and tearing of the eyes.

Chronic symptoms: Cytotoxic agent: Suspected of causing cancer. May damage fertility or the unborn child. May cause damage to the following organs through prolonged or repeated exposure:. Blood.

Indication of any immediate medical attention and special treatment needed

Treat symptomatically. In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible).

5. FIRE-FIGHTING MEASURES

Extinguishing media

Suitable Extinguishing Media: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

Unsuitable extinguishing media: None known. Specific hazards arising from the chemical

Fire hazard: Not flammable.

Explosive hazard: Not an explosive.

Reactivity: Hazardous reactions will not occur under normal conditions.

Hazardous combustion products: Carbon oxides. Nitrogen oxides. Hydrogen fluoride. Hydrogen chloride.

Advice for firefighters

22-September-2023

Precautionary measures in case of fire: Standard procedure for chemical fires. **Firefighting instructions:** Use water spray or fog; do not use straight streams.

Protection of Firefighters: Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear.

Other Information: Refer to Section 9 for flammability properties.

2/6

Gemcitabine Injection NA SDS

6. ACCIDENTAL RELEASE MEASURES

This is a pharmaceutical product in its final form. The risk of harmful exposure in the workplace is limited; however, the following guidance may be used as needed.

Personal precautions, protective equipment and emergency procedures

Personal precautions: Ensure adequate ventilation. Use personal protective equipment as required. Evacuate personnel to safe areas.

For non-emergency personnel

Personal Protective Equipment: Use personal protective equipment as required.

Emergency procedures: Evacuate personnel to safe areas.

For emergency responders

Personal Protective Equipment: Use personal protective equipment as required.

Emergency procedures: Evacuate personnel to safe areas. Ventilate the area. Eliminate all ignition sources if safe to do so.

Other Information: Refer to protective measures listed in Sections 7 and 8.

Environmental precautions

Do not flush into surface water or sanitary sewer system. Should not be released into the environment. See Section 12 for additional Ecological Information.

Methods and material for containment and cleaning up

Methods for containment: Prevent further leakage or spillage if safe to do so.

Methods for cleaning up: Use appropriate personal protective equipment (PPE). Carefully shovel or sweep up spilled material and place in suitable container. Avoid generating dust. For spills:. Soak up with inert absorbent material. Use clean non-sparking tools to collect absorbed material. Avoid breathing dust or spray mist.

Prevention of secondary hazards: Clean contaminated objects and areas thoroughly observing environmental regulations.

Reference to other sections

See section 8 for more information. See section 13 for more information.

7. HANDLING AND STORAGE

Precautions for safe handling

Patients/Consumers: Patients should adhere to the instructions provided within the product information insert or product label for appropriate consumer-specific information about this product when used according to the physician's directions.

Advice on safe handling: Handle in accordance with good industrial hygiene and safety practice. Avoid contact with skin, eyes or clothing. Do not eat, drink or smoke when using this product. Remove contaminated clothing and shoes. Ensure adequate ventilation.

Conditions for safe storage, including any incompatibilities

Storage Conditions: Store under refrigeration at 2°C to 8°C (36°F to 46°F). Do not freeze. Keep out of reach of children. Store locked up. **Specific end use(s):** Pharmaceutical. Use only as directed. Refer to product insert for usage instructions and product information.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

This is a pharmaceutical product in its final form. The risk of harmful exposure in the workplace is limited; however, the following guidance may be used as needed.

Control parameters

Exposure Limits: No information available

Exposure controls

Appropriate engineering controls: Site-specific risk assessments should be conducted to determine the appropriate exposure control measures. If applicable, use process enclosures, local exhaust ventilation, or other engineering controls to maintain airborne levels below recommended exposure limits.

Individual protection measures, such as personal protective equipment

Hand protection: Wear suitable gloves.

Eye/face protection: Safety glasses with side shields are recommended for medical or industrial exposures.

Skin and body protection: Wear suitable protective clothing. **Respiratory protection:** Use appropriate respiratory protection.

General hygiene considerations: Do not eat, drink or smoke when using this product. Wash hands before breaks and immediately after

handling the product.

9. PHYSICAL AND CHEMICAL PROPERTIES

Information on basic physical and chemical properties

Physical state: Liquid

Appearance: No data available
Color: No information available

Odor: No data available
Odor threshold: No data available

Gemcitabine Injection NA SDS

pH: No data available Melting point / freezing point: No data available Boiling point / boiling range: No data available Flash point: No data available **Evaporation rate:** No data available Flammability (solid, gas): No data available **Upper flammability limit:** No data available Lower flammability limit: No data available Vapor pressure: No data available Vapor density: No data available Relative density: No data available Water solubility: No data available Solubility in other solvents: No data available **Partition coefficient:** No data available **Autoignition temperature:** No data available **Decomposition temperature:** No data available **Kinematic viscosity:** No data available **Dynamic viscosity:** No data available **Explosive properties:** No data available No data available **Oxidizing properties: Other Information**

VOC Content (%): No data available

10. STABILITY AND REACTIVITY

Reactivity

Hazardous reactions will not occur under normal conditions.

Chemical stability

Stable under normal conditions.

Possibility of hazardous reactions

None under normal processing.

Conditions to avoid

Extremes of temperature and direct sunlight.

Incompatible materials

Strong oxidizing agents, strong acids, and strong bases.

Hazardous decomposition products

Decomposition will not occur under normal conditions.

11. TOXICOLOGICAL INFORMATION

Information on toxicological effects

Information on likely routes of exposure

Inhalation: Specific test data for the substance or mixture is not available.

Ingestion: May be harmful if swallowed. Eye contact: May cause irritation. Skin contact: May cause irritation.

Symptoms related to the physical, chemical and toxicological characteristics

Symptoms: May cause skin irritation. May cause redness and tearing of the eyes.

Delayed and immediate effects as well as chronic effects from short and long-term exposure

Skin corrosion/irritation: Based on available data, the classification criteria are not met.

Serious eve damage/eve irritation: Based on available data, the classification criteria are not met. **Respiratory or skin sensitization:** Based on available data, the classification criteria are not met.

Germ cell mutagenicity: Contains a known or suspected mutagen. **Carcinogenicity:** Contains a known or suspected carcinogen.

Reproductive toxicity: Contains a known or suspected reproductive toxin. May impair fertility. May cause harm to the unborn child.

STOT - single exposure: Based on available data, the classification criteria are not met.

STOT - repeated exposure: Causes damage to organs through prolonged or repeated exposure: Bone marrow.

Aspiration hazard: Based on available data, the classification criteria are not met.

Numerical measures of toxicity Acute toxicity: No information available

12. ECOLOGICAL INFORMATION

Ecotoxicity

Gemcitabine Injection NA SDS

No information available.

Persistence and degradability

No information available.

Bioaccumulation

No information available.

Mobility

No information available.

Other adverse effects

No information available.

13. DISPOSAL CONSIDERATIONS

Waste treatment methods

Dispose of contents/container in accordance with local, regional, national, and international regulations as applicable. Dispose of waste in accordance with environmental legislation. Do not flush into surface water or sanitary sewer system.

14. TRANSPORT INFORMATION

Transportation requirements can vary based on numerous factors such as regional regulations and shipment volume. It is the responsibility of the transporting organization to ensure compliance with all applicable laws and regulations regarding the transportation of this product.

DOT Not regulated TDG Not regulated **IATA** Not regulated Not regulated **IMDG**

15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

International Regulations

Ozone-depleting substances (ODS): Not applicable Persistent Organic Pollutants: Not applicable The Rotterdam Convention: Not applicable

US Federal Regulations

SARA 313: Section 313 of Title III of the Superfund Amendments and Reauthorization Act of 1986 (SARA). This product does not contain any chemicals which are subject to the reporting requirements of the Act and Title 40 of the Code of Federal Regulations, Part 372.

CWA (Clean Water Act)

This product does not contain any substances regulated as pollutants pursuant to the Clean Water Act (40 CFR 122.21 and 40 CFR 122.42).

CERCLA

This material, as supplied, does not contain any substances regulated as hazardous substances under the Comprehensive Environmental Response Compensation and Liability Act (CERCLA) (40 CFR 302) or the Superfund Amendments and Reauthorization Act (SARA) (40 CFR 355). There may be specific reporting requirements at the local, regional, or state level pertaining to releases of this material.

U.S. State Right-to-Know Regulations

US State Regulations: This product does not contain any substances regulated by state right-to-know regulations

This product has been classified in accordance with the hazard criteria of the Controlled Products Regulations (CPR) and the SDS contains all the information required by the CPR.

16. OTHER INFORMATION

Revision Date: 22-September-2023

Other Information: This document has been prepared in accordance with standards for workplace safety. The

precautionary statements and warning included might not apply in all cases. Your needs may vary

5/6

depending on the potential for exposure in your workplace.

Key or legend to abbreviations and acronyms used in the safety data sheet:

Legend, Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

TWA: TWA (time-weighted average) STEL: STEL (Short Term Exposure Limit)

Party responsible for the preparation of this document:

Mylan Global Environmental, Health, and Safety Department - Occupational Toxicology

Phone number: +1 304-559-2595

22-September-2023

Gemcitabine Injection NA SDS

This SDS has been prepared for occupational exposure and intended to address some end-user concerns; however, patients/consumers are also strongly encouraged to review the product information insert or product label for consumer-specific information about this product. Patients/Consumers: Refer to the package insert or product label for appropriate consumer-specific information about this product when used according to manufacturer's directions. To the best of our knowledge, the information contained herein is accurate. However, neither the above named supplier nor any of its subsidiaries assumes any liability whatsoever for completeness of the information herein. Final determination of suitability of any material is the sole responsibility of the user. All materials may present unknown hazards and should be used with caution. Although certain hazards are described herein, we cannot guarantee that these are the only hazards that exist.

Viatris GEHS NA GHS SDS